Výsledky vyhledávání - "Benedict Moore"

Akademický článek

Getting Blended Finance to Where It’s Needed: The Case of CBNRM Enterprises in Southern Africa

Autor: Jessica Smith, Mikael Samuelson, Benedict Moore Libanda, Dilys Roe, Latif Alhassan

Publikováno v: Land, Vol 11, Iss 5, p 637 (2022)

Blended finance aims to unlock additional private finance for the sustainable development goals (SDGs), however, it has not yet reached the anticipated scale to deliver on SDG 15: Life on Land. So far, blended finance approaches have not been fully a

Externí odkaz: https://doaj.org/article/abc226996245407c89fcd4fe9a2c56d6

Zobrazit plný text záznamu

Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment

Autor: Kaenat Mulla, Sheima Farag, Benedict Moore, Sheila Matharu, Kate Young, James Larkin, Sanjay Popat, Daniel Laurence Morganstein

Aims We systematically studied the presence of hyperglycaemia during treatment with Immune Checkpoint Inhibitors (ICPI) for cancer, in those with and without diabetes at baseline, and determined the cause of new-onset hyperglycaemia, Methods Retrospe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d230f6aec5cb141ec8973b8f9d18d46d
http://hdl.handle.net/10044/1/102827

Zobrazit plný text záznamu

Getting Blended Finance to Where It’s Needed: The Case of CBNRM Enterprises in Southern Africa

Autor: Smith, Jessica, Samuelson, Mikael, Libanda, Benedict Moore, Roe, Dilys, Alhassan, Latif

Publikováno v: Land

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3158::9c788e3087abb15f9cd2d0aae082c7db
http://hdl.handle.net/11427/36654

Zobrazit plný text záznamu

FRI0666 RHEUMATIC COMPLICATIONS OF IMMUNE CHECKPOINT INHIBITOR THERAPY: A CASE SERIES

Autor: Margaret Callan, Matthew Ho, Benedict Moore

Publikováno v: Epidemiology, risk factors for disease or disease progression.

Background Immune checkpoint inhibitor therapy reduces negative signals of T cell activation and enables tumour-specific T cells to mount a more effective response. Use of these drugs in management of malignancy has been associated with the developme

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::77f38c93767b252dd3a5c5e11481a33e
https://doi.org/10.1136/annrheumdis-2019-eular.2397

Zobrazit plný text záznamu